Doxorubicin (Adriamycin)
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Aggressive Non-Hodgkin lymphoma
- Basal cell and squamous cell skin cancer
- Bladder cancer
- Bone cancer
- Breast cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Follicular lymphoma
- Hepatobiliary cancer
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Mantle cell lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- Renal cancer
- Sarcoma
- Small cell lung cancer
- Thymoma
- Transplant conditioning regimens
- Uterine cancer
Patient drug information
- Doxorubicin (Adriamycin) patient drug information (Chemocare)[3]
- Doxorubicin (Adriamycin) package insert page 1[1]
- Doxorubicin (Adriamycin) patient drug information (UpToDate)[4]
Also known as
Adriablastina, Adriacept, Adriacin, Adriamycin HS, Adriamycin PFS, Adriamycin R-D, Adriamycin R.D.F, Adriamycin RDF, Adriblastin, Adriblastina, Adriblastina DR, Adriblastina R.D., Adriblastina R.T.U., Adriblastina RD, Adriblastina RTU, Adriblastine, Adriblastine RTU, Adriblastin PFS, Adriblastin RD, Adricept, Adricin, Adrim, Adrimedac, Adrosal, Antraciclin, Biorrub, Biorubina, Cadria, Carcinocin, Cloridrato DE, Doxorrubicina Colhidrol, Daxotel, Deldoxin, Dicladox, Dobicin, Dobixin, Doxo, Doxobin, Doxo Cell, Doxocris, Doxokebir, Doxolem, Doxolem RU, Doxonolver, Doxor, Doxorrubicina, Doxoruben, Doxorubicina, Doxorubicina Asofarma, Doxorubicina Ferrer, Doxorubicina Filaxis, Doxorubicina Gador, Doxorubicina Servycal, Doxorubicina Tedec, Doxorubicin Bigmar, Doxorubicin Comp, Doxorubicin DBL, Doxorubicine, Doxorubicin Ebewe, Doxorubicine Bristol, Doxorubicine Dakota, Doxorubicine G GAM, Doxorubicine HCl Eurocept, Doxorubicine Hydrochloride, Doxorubicine Sandoz HCl, Doxorubicine Teva, Doxorubicin FOT, Doxorubicin Funk, Doxorubicin HCl, Doxorubicin Hydrochloride, Doxorubicin KMP, Doxorubicin Meda, Doxorubicin Pharmachemie, Doxorubicin Teva, Doxorubicinum, Doxorubin, Doxotec, Doxtie, Duxocin, Evacet, Farmiblastina, Fauldoxo, Flavicina, hydroxydaunorubicin, Ifadox,L-Doxorubicin, Lipodox, Lyphidox, Myocet, Nagun, Neoxane, Nuaze, Oncodria, Onkodox, Onkostatil, Pallagicin, Ranxas, Rastocin, Ribodoxo, Ribodoxo-L, Roxorin, Rubex, Trav Doxorubicin, Urokit Doxo Cell Loesung, Varidoxo, or Zodox.
References
- Drug index
- Chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- Vesicant chemotherapy
- Acute lymphocytic leukemia medications
- Basal cell and squamous cell skin cancer medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Hepatobiliary cancer medications
- Hodgkin lymphoma medications
- Multiple myeloma medications
- Non-Hodgkin lymphoma medications
- Renal cancer medications
- Sarcoma medications
- Thymoma medications
- Uterine cancer medications